Objective To investigate the clinical effect of Buyang Huanwu Decoction in the treatment of Parkinson's disease (PD). Methods A total of 43 patients with PD were randomly divided into treatment group with 22 patients and control group with 21 patients. The patients in the control group were given Madopar, benzhexol hydrochloride, and amantadine based on their condition, and those in the treatment group were given oral Buyang Huanwu Decoction one dose a day in two divided doses in addition to the Western medicine treatment in the control group. The course of treatment was 6 weeks. The two groups were compared in terms of modified Hoehn-Yahr stage and unified Parkinson's disease rating scale (UPDRS) score every two weeks. Results At the end of weeks 2, 4, and 6 of treatment, both groups had gradual reductions in modified Hoehn-Yahr stage and UPDRS Ⅲ score, and from enrollment to the end of weeks 4 and 6 of treatment, both groups had significant reductions in modified Hoehn-Yahr stage and UPDRS Ⅲ score (P<0.05). There was no significant difference in modified Hoehn-Yahr stage between the two groups at each time point (P>0.05), and at the end of weeks 2, 4, and 6 of treatment, the treatment group had a significantly lower UPDRS Ⅲ score than the control group (P<0.05). Conclusion Buyang Huanwu Decoction has a good anti-PD effect and may accelerate the anti-PD effect of Madopar, but further studies are needed to clarify the specific mechanism.